Control of Therapy of Acne Papulopustulosa by Visible Light With Waterfiltered Infrared and / or Adapalen (Differin Gel)

NCT ID: NCT00237978

Last Updated: 2009-05-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-09-30

Study Completion Date

2009-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to investigate the effectivity of visible light in combination with waterfiltered infrared in treating acne papulopustulosa. The reduction of inflammatory and non-inflammatory lesions within 8 weeks will be measured and compared with the standard treatment with Adapalene.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acne Papulopustulosa

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

VIS and wIRA

Group Type ACTIVE_COMPARATOR

VIS and wIRA

Intervention Type RADIATION

2

VIS, wIRA and Adapalen

Group Type ACTIVE_COMPARATOR

Adapalen

Intervention Type DRUG

VIS and wIRA

Intervention Type RADIATION

3

Adapalen

Group Type ACTIVE_COMPARATOR

Adapalen

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Adapalen

Intervention Type DRUG

VIS and wIRA

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Mild to moderate acne papulopustulosa according to Burton Scale Stage 3 to 4
* At least 5 inflammatory and 5 non-inflammatory lesions in the face
* Age \>= 14 years

Exclusion Criteria

* pregnant and nursing women
* Antiandrogen therapy
* therapy with antibiotics within the last 4 weeks
* therapy with retinoids within the last 6 months
* natural or artificial UV-therapy within the last 4 weeks
* severe acne papulopustulosa according to Burton Scale 5 or 6
* Severe systemic condition
* Secondary acne
Minimum Eligible Age

14 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Technische Universität Dresden

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Technical University Dresden

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Roland Aschoff, MD

Role: PRINCIPAL_INVESTIGATOR

Technische Universität Dresden, Fetscher Str. 74, 01307 Dresden, Germany

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden

Dresden, Saxony, Germany

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Roland Aschoff, MD

Role: CONTACT

0049-351-458 ext. 2007

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Roland Aschoff, MD

Role: primary

0049-351-458 ext. 2007

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TUD-Akne02-003

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.